Selected Management Issues of Patients with Hodgkin Lymphoma

Evidence-Based Hematology

Volumn , Issue , 2009, Pages 365-371

  Meyer, Ralph M ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

BEACOPP; BEACOPP regimens with MOPP ABVD like regimen comparison; EORTC H8 F trial; Limited stage Hodgkin lymphoma treated with combined modality therapy; Management of Hodgkin lymphoma; Optimum management of patients with untreated advanced stage Hodgkin lymphoma; Prednisone and procarbazine to ABV (ABVPP); Trials testing chemotherapy

Indexed keywords

EID: 84891017783     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300857.ch46     Document Type: Chapter

References (46)

1. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol. 2005;23:6400-408.
2. Meyer RM, Ambinder RF, Stroobants S. Hodgkin' lymphoma: evolving concepts with implications for practice. Hematology (Am Soc Hematol Educ Program). 2004;184-202.
3. Ries LAG, Harkins D, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer. cancer. gov/csr/1975 2003/, based on November 2005 SEER data submission, posted to the SEERWeb site, 2006.
4. Gospodarowicz MK, Meyer RM. The management of patients with limited stage classical Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program). 2006;253-258.
5. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-61.
6. Lister TA,CrowtherD, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-36.
7. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol. 2004;5:19-26.
8. Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of earlystageHodgkin's disease: ameta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol. 1998;16:830-43.
9. PressOW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001;19:4238-44.
10. Sieber M, Franklin J, TeschH, et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7 [abstract]. Blood. 2002;100:93a.
11. Hagenbeek A, Eghbali H, Fermé C, et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation ismore effective than subtotal nodal irradiation infavorable supradiaphragmatic clinical stages I-IIHodgkin's disease: preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients [abstract]. Blood. 2000;96:575a.
12. Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. N Engl J Med. 2007;357:1916-27.
13. Santoro A, Bonfante V, Viviani S, et al. Subtotal nodal versus involved field irradiation after 4 cycles of ABVD in early stage Hodgkin's disease [abstract]. Proc Am Soc Clin Oncol. 1996;15:415.
14. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stageHodgkin's disease: longterm results. J Clin Oncol. 2004;22:2835-41.
15. Noordijk EM, Thomas J, FerméC, et al. First results of theEORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma [abstract]. J Clin Oncol. 2005;23:561s.
16. Diehl V, Engert A, Mueller RP, et al. HD10: investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: interim analysis of a randomized trial of the German Hodgkin Study Group [abstract]. J Clin Oncol. 2005;23:561s.
17. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. J Clin Oncol. 2004;22:62-68.
18. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483-89.
19. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634-42.
20. Noordijk EM, Carde P,DupouyN, et al. Combined-modality therapy for clinical stage I or IIHodgkin's lymphoma: long-termresults of the European Organisation forResearch andTreatment of CancerH7randomized controlled trials. J Clin Oncol. 2006;24:3128-35.
21. Meyer RM. Is there convincing evidence for the use of chemotherapy alone in patients with limited-stageHodgkin's lymphoma. Eur J Haematol. 2005;75 Suppl 66:115-20.
22. Macdonald DA, Gospodarowicz MK, Wells WA, et al. Relapse patterns and subsequent outcomes of patients treated on the NCIC CTG HD. 6 (ECOGJHD06)randomized trial evaluatingABVDalone in patientswith limited stageHodgkinLymphoma(HL)[abstract]. Blood. 2005;106:241a.
23. Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998;339:1506-14.
24. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-84.
25. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21:607-14.
26. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of theUnited Kingdom LymphomaGroup LY09 trial. J Clin Oncol. 2005;23:9208-218.
27. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 1998;16:818-29.
28. Aleman BM, Raemaekers JM, Tomisic R, et al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2007;67:19-30.
29. Engert A, Franklin J,Maueller RP, et al. HD12 randomised trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma: an analysis of the German Hodgkin Lymphoma Study Group (GHSG) [abstract]. 2006;108:33a.
30. FermeC,MounierN,CasasnovasO, et al. Long-termresults and competing risk analysis of the H89 trial in patientswith advanced-stageHodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006;107:4636-42.
31. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630-37.
32. Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus theweeklyVAPEC-Bregimen for previously untreatedHodgkin's disease. J Clin Oncol. 2002;20:2988-94.
33. Aviles A, Cleto S, Neri N, et al. Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy. Leuk Lymphoma. 2003;44:1361-65.
34. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate-and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23:9198-207.
35. Johnson P, Hoskin P, Horwich A, et al. Stanford V regimen versus ABVD for the treatment of advanced Hodgkin lymphoma: results of a UK NCRI/LTO randomised phase II trial [abstract]. Blood. 2004;104:93a.
36. Diehl V, Franklin J, PfreundschuhM, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-95.
37. Diehl V, Franklin J,HasencleverD, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998;16:3810-21.
38. Sieniawski M, Reineke T, Josting A, et al. Fertility in male Hodgkin lymphoma patients-a report of German Hodgkin Study Group [abstract]. Blood. 2006;108:34a.
39. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;20:7555-64.
40. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried outby the GermanHodgkin StudyGroup(GHSG)for elderly patientswith advancedHodgkin's disease comparing BEACOPPbaseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16:124-31.
41. Diehl V, Brillant C, Engert A, et al. Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma [abstract]. Blood. 2005;106:240a.
42. Ferme C, Diviné M, Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) III Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial [abstract]. Blood. 2005;106:240a.
43. SieberM,TeschH, PfistnerB, et al. Rapidly alternatingCOPP/ABV/IMEP is not superior to conventional alternating COPP/ABVDin combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol. 2002;20:476-84.
44. Sieber M, Tesch H, Pfistner B, et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004;15:276-82.
45. Saghatchian M, Djeridane M, Escoffre-Barbe M, et al. Very high risk Hodgkin's disease: ABVD (4 cycles) plus BEAM followed by autologous stem cell transplantation and radiotherapy versus intensive chemotherapy (3 cycles) (INT-CT) and RT: four-year results of the GOELAMS H97-GMmulticentric randomized trial [abstract]. J Clin Oncol. 2002;21:263a.
46. Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol. 2003;21:2320-25.